PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

University of Montana leads $12.3 million contract to advance TB vaccine

University of Montana leads $12.3 million contract to advance TB vaccine
2023-10-23
(Press-News.org) MISSOULA – The National Institutes of Health recently awarded a $12.3 million contract to the University of Montana to develop a novel vaccine adjuvant for use in a tuberculosis vaccine. Adjuvants are substances that boost the effectiveness of vaccines.

The five-year award went to UM’s Center for Translational Medicine and its partners. The contract is titled “Development of UM-1098: A Novel Synthetic Th17 Inducing Adjuvant and Delivery System.”

“The development and clinical evaluation of safe and effective adjuvants is urgently needed for the advancement of vaccines to combat the ongoing threat of bacterial and fungal infections, including tuberculosis, pertussis and others,” said Jay Evans, director of the UM center. “TB affects a significant portion of the global population, and the only licensed vaccine, BCG, has limited effectiveness. Thus the development of an effective vaccine is critical to end the global TB epidemic.”

According to the World Health Organization, 1.6 million people died from TB in 2021. Worldwide, TB is the 13th leading cause of death and second leading infectious killer after COVID-19 (above HIV and AIDS).

Drs. Evans and Walid Abdelwahab are the co-principal investigators on the contract, along with their colleagues Drs. David Burkhart, Asia Riel and Blair DeBuysscher with Center for Translational Medicine. The project also includes researchers from the University of Chicago (Dr. Shabaana Khadar), the Texas Biomedical Research Institute (Dr. Smriti Mehra) and Missoula-based Inimmune Corp., a corporate development partner (Drs. Kendal Ryter and Shannon Miller).

Evans said vaccine development for TB and other bacterial and fungal pathogens has been hampered by the lack of appropriate adjuvants and effective formulations. This new contract builds upon a recently completed $13 million NIH Adjuvant Discovery Contract, which identified the lead candidate being advanced toward human clinical trials in the current award.

“This funding represents tremendous support for our continuous research efforts in advancing safe and efficient adjuvants and formulation strategies for further development of vaccine candidates against TB,” Abdelwahab said. “This contract is a strong endorsement of our exceptional vaccine research team at UM.”

The project involves a large vaccine research team at UM with more than two decades of research on improving vaccines through the use of adjuvants and novel delivery systems to ensure vaccines are safely and efficiently delivered to the targeted cells. The UM research will involve both undergraduate and graduate students, providing them with an opportunity to do research on a new vaccine that may have a profound impact on global health.

“There is extraordinary research ongoing at UM that could positively impact the lives of countless people,” Evans said. “Our Vaccine Research Team is dedicated to nurturing and cultivating an interactive research community at UM, specifically geared toward advancing these technologies to help individuals and communities in Montana and across the globe.”

Inimmune is a biotech company located at the University’s business incubator, MonTEC. It will assist with vaccine manufacturing efforts and advancement of this new technology to human clinical trials. The Inimmune efforts will be led by Ryter, the company’s vice president of manufacturing and development.

“Inimmune is very excited to be chosen as a collaborator to advance this exciting new technology,” Ryter said. “Adjuvants and immunomodulators that effectively drive a Th17-biased immune response are not part of the standard vaccine tool kit, and we see this approach as having tremendous potential in developing therapies for some of the most difficult to treat and impactful infectious diseases in the world, such as TB.”

Founded in 2016, Inimmune focuses on the discovery and development of new immunomodulatory therapeutics for treatment of allergic diseases, cancer and infectious disease. Learn more at https://inimmune.com/.

###

MISSOULA – The National Institutes of Health recently awarded a $12.3 million contract to the University of Montana to develop a novel vaccine adjuvant for use in a tuberculosis vaccine. Adjuvants are substances that boost the effectiveness of vaccines.

The five-year award went to UM’s Center for Translational Medicine and its partners. The contract is titled “Development of UM-1098: A Novel Synthetic Th17 Inducing Adjuvant and Delivery System.”

“The development and clinical evaluation of safe and effective adjuvants is urgently needed for the advancement of vaccines to combat the ongoing threat of bacterial and fungal infections, including tuberculosis, pertussis and others,” said Jay Evans, director of the UM center. “TB affects a significant portion of the global population, and the only licensed vaccine, BCG, has limited effectiveness. Thus the development of an effective vaccine is critical to end the global TB epidemic.”

According to the World Health Organization, 1.6 million people died from TB in 2021. Worldwide, TB is the 13th leading cause of death and second leading infectious killer after COVID-19 (above HIV and AIDS).

Drs. Evans and Walid Abdelwahab are the co-principal investigators on the contract, along with their colleagues Drs. David Burkhart, Asia Riel and Blair DeBuysscher with Center for Translational Medicine. The project also includes researchers from the University of Chicago (Dr. Shabaana Khadar), the Texas Biomedical Research Institute (Dr. Smriti Mehra) and Missoula-based Inimmune Corp., a corporate development partner (Drs. Kendal Ryter and Shannon Miller).

Evans said vaccine development for TB and other bacterial and fungal pathogens has been hampered by the lack of appropriate adjuvants and effective formulations. This new contract builds upon a recently completed $13 million NIH Adjuvant Discovery Contract, which identified the lead candidate being advanced toward human clinical trials in the current award.

“This funding represents tremendous support for our continuous research efforts in advancing safe and efficient adjuvants and formulation strategies for further development of vaccine candidates against TB,” Abdelwahab said. “This contract is a strong endorsement of our exceptional vaccine research team at UM.”

The project involves a large vaccine research team at UM with more than two decades of research on improving vaccines through the use of adjuvants and novel delivery systems to ensure vaccines are safely and efficiently delivered to the targeted cells. The UM research will involve both undergraduate and graduate students, providing them with an opportunity to do research on a new vaccine that may have a profound impact on global health.

“There is extraordinary research ongoing at UM that could positively impact the lives of countless people,” Evans said. “Our Vaccine Research Team is dedicated to nurturing and cultivating an interactive research community at UM, specifically geared toward advancing these technologies to help individuals and communities in Montana and across the globe.”

Inimmune is a biotech company located at the University’s business incubator, MonTEC. It will assist with vaccine manufacturing efforts and advancement of this new technology to human clinical trials. The Inimmune efforts will be led by Ryter, the company’s vice president of manufacturing and development.

“Inimmune is very excited to be chosen as a collaborator to advance this exciting new technology,” Ryter said. “Adjuvants and immunomodulators that effectively drive a Th17-biased immune response are not part of the standard vaccine tool kit, and we see this approach as having tremendous potential in developing therapies for some of the most difficult to treat and impactful infectious diseases in the world, such as TB.”

Founded in 2016, Inimmune focuses on the discovery and development of new immunomodulatory therapeutics for treatment of allergic diseases, cancer and infectious disease. Learn more at https://inimmune.com/.

###

END


[Attachments] See images for this press release:
University of Montana leads $12.3 million contract to advance TB vaccine

ELSE PRESS RELEASES FROM THIS DATE:

People who communicate more, show expertise are more likely to be seen as essential team members

2023-10-23
A new study sheds light on the vital role of communication and expertise within organizations, revealing their impact on group performance. Researchers examined how individuals become part of communication networks and the effect of selection processes on group performance. The study found that people who communicated more during training were more likely to be chosen as a central member of the network. In addition, teams that chose their central member performed as well as and often better than teams whose central member was randomly assigned. The study, by researchers ...

Apoptotic cells may drive cell death in hair follicles during regression cycle

Apoptotic cells may drive cell death in hair follicles during regression cycle
2023-10-23
“Revealing the stem cell niche self-renewal dynamics is important not only for understanding tissue homeostasis but also for understanding the initiation of cancer [7].” BUFFALO, NY- October 23, 2023 – A new research paper was published in Oncotarget's Volume 14 on October 19, 2023, entitled, “Apoptotic cells may drive cell death in hair follicles during their regression cycle.” Intravital microscopy in live mice has shown that the elimination of epithelial cells during hair follicle regression involves supra-basal cell differentiation and basal cell apoptosis through synergistic action of TGF-β (transforming ...

$3.6 million NIH award funds research to treat painful diabetic neuropathy

$3.6 million NIH award funds research to treat painful diabetic neuropathy
2023-10-23
COLUMBUS, Ohio – A $3.6 million award from the National Institutes of Health will allow neurosurgical, neurology and neuroscience researchers at The Ohio State University Wexner Medical Center and College of Medicine to test a novel diagnosis and treatment combination for painful diabetic neuropathy. The approach combines spinal cord stimulation with measurement of small fiber nerve activity using a patent-pending device called Detecting Early Neuropathy (DEN). Diabetes is a growing health concern worldwide, ...

Superdeep diamonds provide a window on supercontinent growth

Superdeep diamonds provide a window on supercontinent growth
2023-10-23
Washington, DC—Diamonds contain evidence of the mantle rocks that helped buoy and grow the ancient supercontinent Gondwana from below, according to new research from a team of scientists led by Suzette Timmerman—formerly of the University of Alberta and now at the University of Bern—and including Carnegie’s Steven Shirey, Michael Walter, and Andrew Steele. Their findings, published in Nature, demonstrate that superdeep diamonds can provide a window through space and time into the supercontinent growth and formation ...

American Cancer Society awards pilot funding to University of Cincinnati Cancer Center for early-stage investigators

American Cancer Society awards pilot funding to University of Cincinnati Cancer Center for early-stage investigators
2023-10-23
The American Cancer Society has awarded the University of Cincinnati Cancer Center an Institutional Research Grant. Cancer Center member David Plas, PhD, is primary investigator for the grant, with members Maria Czyzyk-Krzeska, MD, PhD, and Kathryn Wikenheiser-Brokamp, MD, PhD, serving as co-principal investigators. The American Cancer Society awards Institutional Research Grants to academic and nonprofit organizations that have a track record of outstanding cancer research and a pool of experienced researchers who can mentor junior faculty. The purpose is to support early-stage ...

Climate is increasing risk of high toxin concentrations in Northern US lakes

Climate is increasing risk of high toxin concentrations in Northern US lakes
2023-10-23
Washington, DC— As climate change warms the Earth, higher-latitude regions will be at greater risk for toxins produced by algal blooms, according to new research led by Carnegie’s Anna Michalak, Julian Merder, and Gang Zhao. Their findings, published in Nature Water, identify water temperatures of 20 to 25 degrees Celsius (68 to 77 degrees Fahrenheit) as being at the greatest risk for developing dangerous levels of a common algae-produced toxin called microcystin.   Harmful algal blooms result when bodies of water get overloaded with nitrogen and phosphorus ...

Breastfeeding in the setting of substance use

Breastfeeding in the setting of substance use
2023-10-23
The Academy of Breastfeeding Medicine (ABM) has released new literature-based recommendations related to breastfeeding in the setting of substance use and substance use disorder (SUD) treatments. The new clinical protocol is published in the peer-reviewed journal Breastfeeding Medicine. Click here to read the article now. Miriam Harris, MD and Elisha Wachman, MD, from Boston Medical Center, and coauthors, provide breastfeeding recommendations in the setting of non-prescribed opioid, stimulant, sedative-hypnotic, alcohol, nicotine, and cannabis use, and SUD treatments. They also offer guidance on the use of toxicology testing in breastfeeding ...

New exoplanet-informed research sets clearer bounds on the search for radio technosignatures

New exoplanet-informed research sets clearer bounds on the search for radio technosignatures
2023-10-23
A new study leverages the NASA Exoplanet Archive and planetary system simulations to make narrowband SETI searches more efficient. October 23, 2023, Mountain View, CA -- In a new study published in the Astronomical Journal, researchers used the known population of exoplanets and extrapolated to the much larger, unknown population of exoplanets to set better thresholds for planetary effects on signals from ETIs (extraterrestrial intelligences). The prior recommendation for the threshold “drift rate” contribution, caused by a planet’s motion around its host star, was 200 nHz. In this work, lead ...

Navigating the future of skin health: The 14Th International Conference on Skin Ageing & Challenges 2023

Navigating the future of skin health: The 14Th International Conference on Skin Ageing & Challenges 2023
2023-10-23
Lisbon, Portugal – 23 October, 2023 The International Society of Microbiota (ISM) is proud to present the 14th International Conference on Skin Ageing & Challenges 2023. This monumental event will unfold at the Altis Grand Hotel in Lisbon, Portugal, and virtually, on November 9-10, 2023. Skin ageing, a multifaceted issue combining both basic research, mechanistic, clinical aspects and health concerns, is gaining significant attention in the scientific community. This year’s conference promises to be a beacon of innovation, ...

Gut fungi's lasting impact on severe COVID-19 immune response

2023-10-23
Certain gut-dwelling fungi flourish in severe cases of COVID-19, amplifying the excessive inflammation that drives this disease while also causing long-lasting changes in the immune system, according to a new study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian. This discovery identifies a group of patients who may benefit from specialized, but yet-to-be determined treatments. Utilizing patient samples and preclinical models, the research team determined that the growth of fungi in the intestinal ...

LAST 30 PRESS RELEASES:

Multi-resistance in bacteria predicted by AI model

Tinker Tots: A citizen science project to explore ethical dilemmas in embryo selection

Sensing sickness

Cost to build multifamily housing in California more than twice as high as in Texas

Program takes aim at drinking, unsafe sex, and sexual assault on college campuses

Inability to pay for healthcare reaches record high in U.S.

Science ‘storytelling’ urgently needed amid climate and biodiversity crisis

KAIST Develops Retinal Therapy to Restore Lost Vision​

Adipocyte-hepatocyte signaling mechanism uncovered in endoplasmic reticulum stress response

Mammals were adapting from life in the trees to living on the ground before dinosaur-killing asteroid

Low LDL cholesterol levels linked to reduced risk of dementia

Thickening of the eye’s retina associated with greater risk and severity of postoperative delirium in older patients

Almost one in ten people surveyed report having been harmed by the NHS in the last three years

Enhancing light control with complex frequency excitations

New research finds novel drug target for acute myeloid leukemia, bringing hope for cancer patients

New insight into factors associated with a common disease among dogs and humans

Illuminating single atoms for sustainable propylene production

New study finds Rocky Mountain snow contamination

Study examines lactation in critically ill patients

UVA Engineering Dean Jennifer West earns AIMBE’s 2025 Pierre Galletti Award

Doubling down on metasurfaces

New Cedars-Sinai study shows how specialized diet can improve gut disorders

Making moves and hitting the breaks: Owl journeys surprise researchers in western Montana

PKU Scientists simulate the origin and evolution of the North Atlantic Oscillation

ICRAFT breakthrough: Unlocking A20’s dual role in cancer immunotherapy

How VR technology is changing the game for Alzheimer’s disease

A borrowed bacterial gene allowed some marine diatoms to live on a seaweed diet

Balance between two competing nerve proteins deters symptoms of autism in mice

Use of antifungals in agriculture may increase resistance in an infectious yeast

Awareness grows of cancer risk from alcohol consumption, survey finds

[Press-News.org] University of Montana leads $12.3 million contract to advance TB vaccine